Oral Rapamycin Nanoparticles with Enteric Polymer Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral rapamycin preparations face challenges with stability, bioavailability, and reliability due to degradation issues, limiting their effectiveness in treating medical conditions beyond organ transplant rejection, particularly in oncology and neurology.
Innovation Solution
Development of improved encapsulated rapamycin nanoparticles within a protective polymer matrix, using controlled release and stabilization methods such as rapid anti-solvent precipitation and sodium cholate-based molecular aggregations, enhancing stability and bioavailability for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If rapamycin is administered orally in conventional formulations, then it can be given via oral route, but it degrades in acidic stomach conditions and has unreliable bioavailability
Solution Approach 1:
The patent segments the delivery system into two distinct parts: (1) an enteric coating layer that protects rapamycin from stomach acid and dissolves only in intestinal conditions, and (2) a nanoparticle core containing the rapamycin payload. This segmentation allows the drug to survive gastric conditions and release reliably in the intestine, resolving the contradiction between oral administration ease and bioavailability reliability.
Solution Approach 2:
The enteric coating acts as an intermediary protective layer between the acidic stomach environment and the rapamycin nanoparticle core. This intermediary prevents direct contact between acid and the drug, enabling oral administration while ensuring reliable delivery to the intestine where absorption occurs.
2Object-affected harmful factors
If rapamycin is microencapsulated using conventional methods, then protection from acid is provided, but stability and predictable absorption levels are not achieved
Solution Approach 1:
The patent employs a composite structure combining (1) an enteric polymer coating material that provides acid resistance, and (2) a nanoparticle core material that enables controlled release. This composite approach ensures both protection from acid degradation and reliable, predictable absorption by leveraging the complementary properties of each material component.
Solution Approach 2:
The patent controls the dissolution pH parameter of the enteric coating to ensure it remains stable at gastric pH but dissolves predictably at intestinal pH. This parameter control enables reliable protection during stomach transit and predictable release in the intestine, achieving both protection and reliability.
3Stability of the object's composition
If conventional microencapsulation is used, then some protection is provided, but storage stability and biodistribution are insufficient
Solution Approach 1:
The patent uses a nested structure where rapamycin molecules are encapsulated within nanoparticle cores, which are then coated with enteric polymer layers. This nested configuration provides multiple protective barriers that enhance storage stability while maintaining controlled release properties for reliable biodistribution to target tissues.
Solution Approach 2:
The nanoparticle core employs a porous structure that allows controlled diffusion of rapamycin while providing protective encapsulation. This porous architecture enhances storage stability by protecting the drug from degradation while enabling reliable biodistribution through controlled release kinetics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved encapsulated rapamycin nanoparticles demonstrate increased stability, bioavailability, and biodistribution, effectively treating and preventing genetically-predisposed and age-related disorders, including cancer and neurological conditions, with enhanced patient compliance and cost-effectiveness.
Implementation Method 1
The Eudragit S-100 polymer matrix includes a particular methacrylate polymer that is generally stable at pH levels below 7 and was used to protect the rapamycin from degrading in the acidic conditions of the stomach
Implementation Method 2
once the microencapsulated rapamycin entered basic conditions (i.e., pH greater than 7) within the intestines, the matrix would dissolve and, theoretically, the undegraded rapamycin would be absorbed through the intestinal walls
Implementation Method 3
the undegraded rapamycin would be absorbed through the intestinal walls and become bioavailable for its intended medical purposes
Data Source
AI summary
Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders. The embodiments discussed address the present need for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.